A novel series of anilinopyrazoles has been designed based on the X-ray crystal structure analysis. Most compounds from this series not only show sub-nanomolar IC50 values for CDK2, but also demonstrate almost 1000-fold selectivity to other kinases including CDK1. (C) 2003 Elsevier Ltd. All rights reserved.
The present invention relates to anilinopyrazole derivatives, methods for the preparation of such anilinopyrazoles, and use of such anilinopyrazoles in the treatment of certain diseases or conditions. In particular, the present invention relates to a nilinopyrazole derivatives useful as CDK2 inhibitors and use of the anilinopyrazoles in the treatment of disorders mediated by inappropriate CDK2 activity.